RVMD
Revolution MedicinesFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Operating peers and competitors
Source-backed product markets and frozen research comparisons. Valuation comparators remain in the existing peer table.
Loading market evidence...
Research comparisons do not establish forecast usefulness or trading returns.
Compare shared product markets
Membership only; no portfolio weights or estimated losses.
+
Peers tracked
10
U.S. public peers
Grade Position
Below peers
vs peer average
RVMD vs peer average
15/100
RVMD vs. peer average (F vs. C)
Grade spread
A 3 · B 1 · C 3 · D 2 · F 1
Graded peers loaded
Coverage
10 graded
100% of tracked
Peer overview
AMGN is the first available peer comparator.
Amgen is the closest candidate in the packet for a marketed KRAS benchmark because Lumakras gives investors a real-world frame for RAS-targeted oncology commercialization, although Amgen is far more diversified and mature than RVMD.
✓Peer source comes from the stored AI memo or peer model
✓Grades and factor rows use RankAlpha API data when available
✓Missing peer scores remain blank instead of being estimated
✓Side-by-side comparison keeps the data contract visible
RVMD
Revolution Medicines
AMGN
Amgen
Grade
F
D
Momentum
76
94
Value
41
61
Sentiment
25
26
Setup Bias
Net —
-
Market Cap
-
-
Posture
Defensive
Defensive
Grade position vs AMGN
RVMD / AMGN
Grade Position
Below peers
RVMD vs. peer average (F vs. C)
15/100
Momentum
76
AMGNValue
41
AMGNSentiment
25
AMGNRotation landscape
Peers ranked by the order returned from the peer source, with grades from the API.
Rank
Ticker
Company
Grade
Grade score
vs RVMD
AMGN is the first peer returned for this comparison set.